Exenteration as a primary treatment for locally advanced cervical cancer: long-term results and prognostic factors
Related Experiment Video
Updated: Jun 1, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Dirk Michael Forner1, Bjoern Lampe
1Department of Obstetrics and Gynecology, Florence Nightingale Hospital, Kaiserwerther Diakonie, Dusseldorf, Germany. dr.forner@gmx.de
Objective:
Whereas pelvic exenteration is an established therapy for the treatment of recurrent cervical carcinoma, it is not often performed for primary locally advanced cervical cancer (LACC).
Study Design:
This retrospective study analyzed survival data and prognostic factors of 35 patients with LACC who were treated by pelvic exenteration.
Results:
After surgery, 33 patients (97%) were macroscopically free of tumor. In 20 patients, pelvic lymph nodes (LN) were involved, and in 6 of these, metastatic tissue had reached the paraaortal nodes. Overall, the patients' mean 5 year survival was 43%, and the median survival time was 30 months; these values ranged from 15% to 70% and from 15 to 44 months, respectively, depending on LN involvement (P=.006). Pelvic LN involvement was the only significant factor for overall survival found in the multivariate analysis (P=.02).
Conclusion:
In LACC with free LNs and no distant metastases, pelvic exenteration has good long-term results.
More Related Videos
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
06:46Caudal-to-cranial Approach in Laparoscopic Right Hemicolectomy with Complete Mesocolon Excision and D3 Lymph Node Dissection
Published on: January 9, 2026
